Recent Blog Posts

View Post: Concentrated Prolastin-C approved for alpha1-antitrypsin (AAT ...
19 Oct 2009
Phase 2b study of oglemilast for treatment of Chronic Obstructive Pulmonary Disease (COPD). August 19, 2009. Forest Laboratories and Glenmark Pharmaceuticals announced top-line results from a Phase 2b dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). ... Intal Inhaler discontinued. August 04, 2009. King Pharmaceuticals has decided to discontinue the manufacturing of Intal Inhaler (cromolyn sodium inhalation aerosol). ...
View Blog: Latest articles from MPR News - http://www.empr.com/

---

View Post: RESPIRATORY DRUGS
28 Oct 2009
Beta-2 Selective Agonists  Long acting:  Salmeterol, formoterol  Given b y inha lat io n  DOA: 12 ho urs o r m or e Intera c t with co rtico st ero ids to im pro ve asthm a c on tro l    Salmeterol-fluticasone ... quarternary ammonium derivative of atropine Tiotro pium – structural analog of ipratr opium, approv ed for COPD, permits once daily dosing Delivered b y aerosol (metered dose inhaler/nebulizer) Slightly less effective than beta agonist     ...
View Blog: Recent plicks from myplick.com - http://www.myplick.com/

---

View Post: Advair Diskus (Fluticasone Propionate) Drug Information: Uses ...
19 Jun 2008
Data from a large placebo-controlled US study that compared the safety of salmeterol (SEREVENT® Inhalation Aerosol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol ..... To be enrolled, all of the patients had to have had a COPD exacerbation in the previous 12 months. In this trial, 88% of the patients treated with ADVAIR DISKUS and 86% of the patients treated with salmeterol reported an adverse event. ...
View Blog: RxList - News and Features - http://www.rxlist.com/script/main/hp.asp

---

View Post: USPharmacist.com > Management Strategies in Stable COPD
26 Jan 2009
Inhaled beta2 agonists have a fairly rapid onset of action. Short-acting beta2 agonists such as albuterol have a duration of action of 4 to 6 hours, while long-acting beta2 agonists (salmeterol, formoterol, and arformoterol) have a duration of ..... In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest. 1994;105:1411-1419. ...
View Blog: Untitled - http://www.uspharmacist.com/home/

---

View Post: AstraZeneca submits an sNDA for SYMBICORT® for COPD indication
30 Apr 2008
... to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) . ... Data from a large placebo-controlled U.S. study compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients ...
View Blog: AZ US news feed - http://www.astrazeneca-us.com/

---

View Post: Video: COPD Landmark Trial UPLIFT Proves Tiotropium Sustains Lung ...
6 Oct 2008
Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19:209-216. 7. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary ... Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404. Video: http://www.prnewswire.com/mnr/uplift/35106/ ...
View Blog: Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html

---

View Post: Long-Acting Bronchodilator Therapy for the Treatment of Chronic ...
1 Dec 2008 by Chen, A. M, Bollmeier, S. G, Finnegan, P. M  
The first inhaled LABA, salmeterol, was initially approved by the Food and Drug Administration (FDA) in 1994, with the addition of an approval for maintenance treatment of bronchospasm associated with COPD in 2002.23 Much of the literature ... aerosols containing sympathomimetics, as these agents had been used in a large proportion of patients.33,34 Today, the GOLD guidelines maintain that studies have found no association between the use of β2-agonists in COPD and ...
View Blog: Annals of Pharmacotherapy current issue - http://www.theannals.com/

---

View Post: AstraZeneca PLC Submits an sNDA for SYMBICORT(R) for COPD ...
30 Apr 2008
(1) Some estimates also suggest that 12 million more people have COPD but are undiagnosed.(1) COPD is a term referring to two serious lung diseases -- emphysema and chronic bronchitis -- that cause a person's airways to become inflamed ... Data from a large placebo-controlled U.S. study compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving ...
View Blog: BioSpace.com Featured News and Stories - http://www.biospace.com/

---

View Post: News release - Boehringer Ingelheim News -
22 Sep 2008
Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA. 2008;300:1439-1450. ... Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404. 13 Pocket Guide to COPD diagnosis, management, and prevention – A guide for healthcare professionals. ...
View Blog: Boehringer Ingelheim RSS-Newsfeed - http://www.boehringer-ingelheim.com/

---

View Post: Asthma - Getting the Most out of Dry Powder Inhaler for Asthma and ...
31 Oct 2008
New York, NY April 3, 2008 -- Proper technique is the key to benefiting from dry powder inhalers (DPIs) that treat chronic obstructive pulmonary disease (COPD) and asthma. But data presented at the annual meeting of the American College ... Compared with aerosol metered dose inhalers, DPIs are considered "user-friendly": They don't require coordination between breathing in and squeezing the inhaler to release medication, and DPIs rely on your breath rather than chemical ...
View Blog: rss title www.newsguide.us - http://www.newsguide.us/

---